BioFire Respiratory Panel with COVID Target Scores CE Mark
July 17, 2020
BioMerieux announced that Utah-based BioFire’s Respiratory Panel 2.1 plus, which tests for SARS-CoV-2 and 23 pathogens encompassing 19 viruses, and four bacteria that cause the most frequent respiratory tract infections, has received CE marking.
“It’s exciting to see the advances that BioFire is making in COVID-19 and infectious disease diagnostics,” said Kelvyn Cullimore, president and CEO of BioUtah. “And it’s happening right here in Utah.”
An earlier version of the test received EUA from the FDA in May. These panel tests, which are designed to detect and differentiate between SARS-CoV-2 and a number of other viral and bacterial respiratory pathogens, get results in about 45 minutes, and are part of a larger BioFire COVID-19 test menu. In March, the company was granted EUA for BioMerieux’s’ subsidiary BioFire Defense’s’ rapid COVID-19 assay, which has the same 45 minute runtime.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
